Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.47 |
| ▸ | BAD | Q92934 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | ALPG | P10696 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28043394 | 0.86 | NPC1 (0.53) | CES2CES1BCL2L1BADNPC1 | |
| SCHEMBL25214258 | 0.85 | CES2 (0.50) | CES2CES1BCL2L1BADNPC1 | |
| SCHEMBL526237 | 0.82 | CES2 (0.46) | CES2CES1BCL2L1BADNPC1 | |
| SCHEMBL7028909 | 0.81 | ALDH1A1 (0.54) | CES2CES1NPC1SLC6A2SLC6A3 | |
| SCHEMBL204960 | 0.80 | CES2 (0.54) | CES2CES1BCL2L1BADNPC1 | |
| SCHEMBL6726501 | 0.80 | CES2 (0.54) | CES2CES1BCL2L1BADNPC1 | |
| SCHEMBL649287 | 0.80 | KMT2A (0.55) | CES2CES1NPC1ALDH1A1HPGD | |
| SCHEMBL8823334 | 0.80 | KMT2A (0.55) | CES2CES1NPC1ALDH1A1HPGD | |
| SCHEMBL8683450 | 0.79 | ALOX15 (0.52) | CES2CES1CA1CA2ALDH1A1 | |
| SCHEMBL4457802 | 0.79 | SLC6A3 (0.53) | CES2CES1SLC6A2SLC6A3CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118652169-A | Preparation method of 4- (4-fluorophenyl) -4- (2-fluorophenyl) butyric acid | 湖南玉新药业有限公司 | 2024-09-17 | — | — | CN | disclosed |
| CN-117510322-A | Preparation method of 4- (4-fluorophenyl) -4- (2-fluorophenyl) butyric acid | 湖南中南制药有限责任公司 | 2024-02-06 | — | — | CN | disclosed |
| CN-109942473-A | A kind of method of catalyst-free synthesis lactam derivatives | 贵州大学 | 2019-06-28 | — | — | CN | disclosed |
| US-20170037016-A1 | GUANIDINE COMPOUNDS AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | ABBVIE DEUTSCHLAND (DE) | 2017-02-09 | — | — | US | disclosed |
| US-9475782-B2 | Guanidine compounds, and use thereof as binding partners for 5-HT5 receptors | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-10-25 | — | — | US | disclosed |
| EP-1716127-B1 | GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | ABBVIE DEUTSCHLAND (DE) | 2014-08-06 | — | — | EP | disclosed |
| US-20130324537-A1 | GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | ABBOTT LABORATORIES (US) | 2013-12-05 | — | — | US | disclosed |
| US-8481576-B2 | Guanidine compounds, and use thereof as binding partners for 5-HT5 receptors | ABBOTT GMBH & CO. KG (DE) | 2013-07-09 | — | — | US | disclosed |
| US-8431604-B2 | Guanidine compounds, and use thereof as binding partners for 5-HT5 receptors | ABBOTT GMBH & CO. KG (DE) | 2013-04-30 | — | — | US | disclosed |
| EP-2380885-A1 | Guanidine compounds and use of same as binding partners for 5-HT5 receptors | Abbott GmbH & Co. KG (DE) | 2011-10-26 | — | — | EP | disclosed |
| EP-1716127-A2 | GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | Abbott GmbH & Co. KG (DE) | 2006-11-02 | — | — | EP | disclosed |
| US-20060229280-A1 | Endothelin antagonists | ABBVIE INC. | 2006-10-12 | — | — | US | disclosed |
| US-20060116406-A1 | 7-(1,3-thiazol-2-yl)thio!-coumarin derivatives and their use as leukotriene biosynthesis inhibitors | GAREAU YVES | 2006-06-01 | — | — | US | disclosed |
| EP-1636222-A1 | 7-[(1,3-THIAZOL-2-YL)THIO]-COUMARIN DERIVATIVES AND THEIR USE AS LEUKOTRIENE BIOSYNTHESIS INHIBITORS | Merck Frosst Canada Ltd. (CA) | 2006-03-22 | — | — | EP | disclosed |
| US-6946481-B1 | Endothelin antagonists | ABBOTT LABORATORIES (US) | 2005-09-20 | — | — | US | disclosed |
| WO-2005082871-A2 | GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | ABBOTT GMBH & CO. KG (DE) | 2005-09-09 | — | — | WO | disclosed |
| WO-2004108720-A1 | 7- (1, 3-THIAZOL-2-YL)THIO!-COUMARIN DERIVATIVES AND THEIR USE AS LEUKOTRIENE BIOSYNTHESIS INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2004-12-16 | — | — | WO | disclosed |
| US-5877202-A | Indole derivatives useful to treat estrogen-related neoplasms and disorders | AVENTISUB II INC. | 1999-03-02 | — | — | US | disclosed |
| EP-0746544-B1 | NOVEL INDOLE DERIVATIVES USEFUL TO TREAT ESTROGEN-RELATED NEOPLASMS AND DISORDERS | MERRELL PHARMA INC (US) | 1998-09-09 | — | — | EP | disclosed |
| WO-1994026692-A1 | BICYCLIC AMIDE DERIVATIVES AND THEIR USE AS MUSCLE RELAXANTS | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130324537-A1 | GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | HTR5A, GRM5, TAAR5 | CES2 3246/4885CES1 4315/4885BCL2L1 3038/4885 |
| US-20170037016-A1 | GUANIDINE COMPOUNDS AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | HTR5A, GRM5, GRK5 | CES2 3591/4885CES1 4433/4885BCL2L1 2673/4885 |
| US-20060116406-A1 | 7-(1,3-thiazol-2-yl)thio!-coumarin derivatives and their use as leukotriene biosynthesis inhibitors | LTC4S, LTA4H, CYSLTR1 | CES2 1319/4885CES1 67/4885BCL2L1 1801/4885 |
| US-20060229280-A1 | Endothelin antagonists | EDNRA, EDNRB, ECE1 | CES2 1692/4885CES1 1243/4885BCL2L1 4234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.